Blockade of the PD‐L1/PD‐1 interaction achieves a durable response in approximately 30% of patients with ccRCC, and the response seems to be related to the tumor level of PD‐L1 expression 17, 18. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.